Notice of Allowability	Application No.	Applicant(s)
	09/645,835	KEONING ET AL.
	Examiner	Art Unit
	Chih-Min Kam	1653
The MAILING DATE of this communication apperall claims being allowable, PROSECUTION ON THE MERITS IS therewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHT of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate comme GHTS. This application is	n this application. If not included unication will be mailed in due course. THIS
2. The allowed claim(s) is/are <u>25,28-30,33 and 36-38</u> .		
3. The drawings filed on are accepted by the Examiner.		
 4. ☐ Acknowledgment is made of a claim for foreign priority unall all b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give for Correct Declaration of Declaration of Declaration changes required by the Notice of Deaftspers. 	been received. been received in Application to file this communication to file ENT of this application. Itted. Note the attached EX reason(s) why the oath of the submitted.	on No ed in this national stage application from the e a reply complying with the requirements AMINER'S AMENDMENT or NOTICE OF or declaration is deficient.
 (a) ∑ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☐ hereto or 2) ☐ to Paper No./Mail Date 4/3/01. 		
(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT F		
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date	6. Interview S Paper No 8), 7. Examiner's	Informal Patent Application (PTO-152) Summary (PTO-413), /Mail Date 0304 Summary (PTO-413)
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. L Examiner's	Statement of Reasons for Allowance

Art Unit: 1653

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Alan Grant on March 25, 2004.

Examiner's Amendments to the Specification:

Please replace the paragraph at page 5, lines 21-24 with the following paragraph:

Figures 2(a), 2(b) and 2(c) show an alignment between the Sp36 amino acid sequence from *S. pneumoniae* strain N4 (SEQ ID NO: 7) and the homologous sequences from *S. pyogenes* (SEQ ID NO: 2) and *S. agalactiae* (SEQ ID NO: 6). Amino acids identical to those of the polypeptide from *S. pneumoniae* are boxed.

Examiner's Amendments to the Claims:

Claims 9-24 have been cancelled.

Claims 25 and 28 have been amended as follows:

- 25. (Currently amended) An isolated polypeptide comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 4 and wherein said polypeptide binds to an antibody that is specific for Sp36 (SEQ ID NO: 7).
- 28. (Currently amended) An isolated polypeptide comprising an amino acid sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NO: 2 and 4 wherein said polypeptide is [present] identical to that found in an organism selected from the group consisting of Group A streptococci and *Staphylococcus aureus* and wherein said polypeptide binds to an antibody that is specific for Sp36 (SEQ ID NO: 7).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1653

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571) 272-0951. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 308-4227 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Chih-Min Kam, Ph. D. CY/C Patent Examiner

March 25, 2004

PRIMARY EXAMINER